Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19



Rating:

Share or cite this content

Citations should be made in the following way:
M. Gagne (Toronto, Canada), J. Lam Shin Cheung (Toronto, Canada), A. Kouri (Toronto, Canada), L. Boulet (Québec, Canada), J. Fitzgerald (Vancouver, Canada), A. Grill (Toronto, Canada), P. O'Byrne (Hamilton, Canada), S. Gupta (Toronto, Canada). An electronic patient decision aid comparing as-needed budesonide-formoterol combination to regular use of inhaled corticosteroid (ICS) in mild asthma: a rapid-cycle design study. 3559

Member's Comments

No comment yet.

Related content which might interest you: Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice: a randomised real-life study Source: Eur Respir J 2006; 28: Suppl. 50, 613s Year: 2006 Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use? Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007 Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007 First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007 Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Treatment with inhaled corticosteroids (ICS), smoking and asthma control in real clinical practice Source: Annual Congress 2010 - Pharmacological treatment in primary care Year: 2010 Switching to maintenance and reliever inhaled corticosteroid/long acting beta agonist: a real-world pilot evaluation in a regional paediatric difficult asthma clinic. Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world Year: 2020 Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials. Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler Source: ERJ Open Res 2016: 00106-2015 Year: 2016 Healthcare resource use following addition of montelukast to budesonide compared to doubling the dose of budesonide in patients with inadequately controlled asthma (COMPACT trial) Source: Eur Respir J 2004; 24: Suppl. 48, 126s Year: 2004 LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 Evaluation of adherence of patients with asthma to treatment by single combination inhaler Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006 Reframing asthma and inhaled corticosteroids (ICS) to modify treatment beliefs: an online randomised controlled trial Source: International Congress 2018 – Educational tools to improve your practice Year: 2018 Asthma control in general practice with inhaled corticosteroids and long-acting B2-agonists administered as a fixed or free combination at stable dosage: the ALISE survey Source: Eur Respir J 2002; 20: Suppl. 38, 397s Year: 2002 Should asthma guidelines be rewritten for initial controller therapy: a 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and inhaled corticosteroids (ICS) in primary care Source: Annual Congress 2008 - Rationale of self-education in asthma therapy Year: 2008 Treatment with inhaled corticosteroids (ICS) in patients with COPD: possible way of optimisation Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Total costs according to reliever use of formoterol turbuhaler in asthma: results from the RELIEF worldwide randomized effectiveness study, stratified by maintenance medication levels Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002 Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001